182 related articles for article (PubMed ID: 15613445)
1. Identification and validation of cell surface antigens for antibody targeting in oncology.
Carter P; Smith L; Ryan M
Endocr Relat Cancer; 2004 Dec; 11(4):659-87. PubMed ID: 15613445
[TBL] [Abstract][Full Text] [Related]
2. Antibody-based identification of cell surface antigens: targets for cancer therapy.
Loo DT; Mather JP
Curr Opin Pharmacol; 2008 Oct; 8(5):627-31. PubMed ID: 18804182
[TBL] [Abstract][Full Text] [Related]
3. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
4. Antitumor effect of antibody against a SEREX-defined antigen (UOEH-LC-1) on lung cancer xenotransplanted into severe combined immunodeficiency mice.
Mizukami M; Hanagiri T; Yasuda M; Kuroda K; Shigematsu Y; Baba T; Fukuyama T; Nagata Y; So T; Ichiki Y; Sugaya M; So T; Takenoyama M; Sugio K; Yasumoto K
Cancer Res; 2007 Sep; 67(17):8351-7. PubMed ID: 17804751
[TBL] [Abstract][Full Text] [Related]
5. The reverse proteomics for identification of tumor antigens.
Lee SY; Jeoung D
J Microbiol Biotechnol; 2007 Jun; 17(6):879-90. PubMed ID: 18050904
[TBL] [Abstract][Full Text] [Related]
6. Combined staining of TAG-72, MUC1, and CA125 improves labeling sensitivity in ovarian cancer: antigens for multi-targeted antibody-guided therapy.
Chauhan SC; Vinayek N; Maher DM; Bell MC; Dunham KA; Koch MD; Lio Y; Jaggi M
J Histochem Cytochem; 2007 Aug; 55(8):867-75. PubMed ID: 17478446
[TBL] [Abstract][Full Text] [Related]
7. Re-targeting of cytotoxic T lymphocytes and/or natural killer cells to CEA-expressing tumor cells with anti-CEA antibody activity.
Kuroki M; Hachimine K; Huang J; Shibaguchi H; Kinugasa T; Maekawa S; Kuroki M
Anticancer Res; 2005; 25(6A):3725-32. PubMed ID: 16302732
[TBL] [Abstract][Full Text] [Related]
8. Advances in specific immunotherapy for prostate cancer.
Kiessling A; Füssel S; Wehner R; Bachmann M; Wirth MP; Rieber EP; Schmitz M
Eur Urol; 2008 Apr; 53(4):694-708. PubMed ID: 18061335
[TBL] [Abstract][Full Text] [Related]
9. Selection of anti-cancer antibodies from combinatorial libraries by whole-cell panning and stringent subtraction with human blood cells.
Siva AC; Kirkland RE; Lin B; Maruyama T; McWhirter J; Yantiri-Wernimont F; Bowdish KS; Xin H
J Immunol Methods; 2008 Jan; 330(1-2):109-19. PubMed ID: 18096183
[TBL] [Abstract][Full Text] [Related]
10. Multivalency: the hallmark of antibodies used for optimization of tumor targeting by design.
Deyev SM; Lebedenko EN
Bioessays; 2008 Sep; 30(9):904-18. PubMed ID: 18693269
[TBL] [Abstract][Full Text] [Related]
11. Phage display derived human monoclonal antibodies isolated by binding to the surface of live primary breast cancer cells recognize GRP78.
Jakobsen CG; Rasmussen N; Laenkholm AV; Ditzel HJ
Cancer Res; 2007 Oct; 67(19):9507-17. PubMed ID: 17909061
[TBL] [Abstract][Full Text] [Related]
12. The identification and development of specific monoclonal antibodies to squamous cell carcinoma.
Arlen M; Tsang A; Scherrer J; Wolf J; Saric O
Crit Rev Immunol; 2001; 21(1-3):205-14. PubMed ID: 11642605
[TBL] [Abstract][Full Text] [Related]
13. Immunotherapy and gene therapy of cancer using antibodies or their genes against tumor-associated antigens.
Kuroki M; Shibaguchi H; Imakiire T; Uno K; Shirota K; Higuchi T; Shitama T; Yamada H; Hirose Y; Nagata A; Kuroki M
Anticancer Res; 2003; 23(6a):4377-81. PubMed ID: 14666724
[TBL] [Abstract][Full Text] [Related]
14. Brief overview of preclinical and clinical studies in the development of intraperitoneal radioimmunotherapy for ovarian cancer.
Meredith RF; Buchsbaum DJ; Alvarez RD; LoBuglio AF
Clin Cancer Res; 2007 Sep; 13(18 Pt 2):5643s-5645s. PubMed ID: 17875801
[TBL] [Abstract][Full Text] [Related]
15. Derlin-1 is overexpressed on the tumor cell surface and enables antibody-mediated tumor targeting therapy.
Ran Y; Hu H; Hu D; Zhou Z; Sun Y; Yu L; Sun L; Pan J; Liu J; Liu T; Yang Z
Clin Cancer Res; 2008 Oct; 14(20):6538-45. PubMed ID: 18927294
[TBL] [Abstract][Full Text] [Related]
16. Principles and use of anti-CTLA4 antibody in human cancer immunotherapy.
Peggs KS; Quezada SA; Korman AJ; Allison JP
Curr Opin Immunol; 2006 Apr; 18(2):206-13. PubMed ID: 16464564
[TBL] [Abstract][Full Text] [Related]
17. MAD-CT-2 identified as a novel melanoma cancer-testis antigen using phage immunoblot analysis.
Dubovsky JA; Albertini MR; McNeel DG
J Immunother; 2007 Oct; 30(7):675-83. PubMed ID: 17893560
[TBL] [Abstract][Full Text] [Related]
18. MMP11: a novel target antigen for cancer immunotherapy.
Peruzzi D; Mori F; Conforti A; Lazzaro D; De Rinaldis E; Ciliberto G; La Monica N; Aurisicchio L
Clin Cancer Res; 2009 Jun; 15(12):4104-13. PubMed ID: 19509157
[TBL] [Abstract][Full Text] [Related]
19. Anti-tumor antibodies in ovarian cancer.
Luborsky JL; Barua A; Shatavi SV; Kebede T; Abramowicz J; Rotmensch J
Am J Reprod Immunol; 2005 Aug; 54(2):55-62. PubMed ID: 16105096
[TBL] [Abstract][Full Text] [Related]
20. [Contemporary molecular-biological methods of cancer diagnosis and monitoring based on the humoral immune response to tumor-associated antigens].
Shebzukhov IuV; Belousov PV; Khlgatian SV; Sazykin AIu; Kuprash DV; Nedospasov SA
Mol Gen Mikrobiol Virusol; 2007; (2):3-6. PubMed ID: 17600920
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
